Pulmonary arterial hypertension (PAH) is a rare and progressive condition caused by high blood pressure in the arteries that ...

Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies ...

Using nationwide networks, advanced cytokine profiling, and patient clustering, the team screened over 100 PAH patients to ...

Patent covers brilaroxazine use for treating Pulmonary Fibrosis -Similar patents have also been granted in key markets around ...

The former pub landlady from Grenoside, Sheffield, was told she had two to four years to live when she was diagnosed with a ...

Women who were postpartum with venous thromboembolism (VTE) or abnormal ECGs faced a substantially higher risk for pulmonary ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the ...

In treatment-naïve patients with PAH, initial monotherapy improves exercise capacity, hemodynamics, and outcomes when compared with those noted among untreated patients. In patients who are newly ...

The Food and Drug Administration (FDA) has issued a warning that pulmonary hypertension has been reported in infants and newborns treated with Proglycem (diazoxide; Teva) for low blood glucose. The ...

Not being able to catch your breath is scary, but shortness of breath can occur in a wide range of medical conditions, including high blood pressure and pulmonary hypertension. Share on Pinterest ...